hit counter
Actinium Pharmaceuticals, Inc. (ATNM) Stock News Sentiment & Price - Sentifly
ATNM - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Actinium Pharmaceuticals, Inc. (ATNM)

USA
Biotechnology
NYSE
ATNM Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATNM Latest news
PRNewsWire
Neutral
Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
2021-11-04 09:05

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) who are fit for intensive therapy has completed the planned dose escalation and patient enrollment. Patients in the fourth and final dose escalation cohort received 1.0 ?Ci/kg of Actimab-A with the standard CLAG-M dose regimen.

PRNewsWire
Neutral
Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
2021-11-04 09:03

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple abstracts highlighting its Iomab-B and Actimab-A clinical programs have been accepted for presentation at the 63 American Society of Hematology (ASH) Annual Meeting being held in person and virtually in Atlanta, Georgia, December 11 – 14, 2021. "We have made good progress this year in advancing Iomab-B and Actimab-A across our three active clinical trials including completing patient enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B.

PRNewsWire
Neutral
Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference
2021-10-01 09:00

NEW YORK, Oct. 1, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021). Actinium's abstract titles and presentation logistics are as follows: Title: Enhancement of the anti-tumor effects of CD47 blockade in solid tumors by combination with targeted radioimmunotherapy Poster Number: 589 Location: Poster Hall Dates and Times: 11/12/2021 - 11/14/2021, 7:00 am - 5:00 pm Title: Anti-CD33 actinium-225 targeted radioimmunotherapy enhances the biologic activity of anti-CD47 antibody immunotherapy in preclinical models of acute myeloid leukemia Poster Number: 590 Location: Poster Hall Dates and Times: 11/12

PRNewsWire
Neutral
Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th
2021-09-28 08:00

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, which is being held from September 27 th to 30th.

PRNewsWire
Neutral
Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates
2021-09-27 08:00

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities.

PRNewsWire
Neutral
Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel
2021-09-23 09:00

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple senior leadership appointments including Arun Swaminathan, Ph.D.

PRNewsWire
Neutral
Actinium to Present at Four Upcoming Investor Conferences
2021-09-20 08:36

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at four upcoming investor conferences.

Benzinga
Positive
BWXT Medical, Bayer AG Ink Agreement On Actinium-225
2021-09-16 10:24

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com Trending

PRNewsWire
Neutral
Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B
2021-09-15 07:00

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131.

Seeking Alpha
Positive
Actinium: A Story Of Delays And Promises, About To Come To Fruition
2021-07-15 09:21

Actinium has taken years to bring its therapy to (near) the market. However, there are no serious challenges to the data we have seen so far.

Loading more news...